Last reviewed · How we verify

NCT03493165

Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)

NO LONGER AVAILABLE Last updated 28 May 2025
What this trial tests

trial testing Everolimus in Uterine Sarcoma. No longer available.

Quick facts

Lead sponsorThe University of Texas Health Science Center at San Antonio
StatusNO LONGER AVAILABLE
Study typeEXPANDED_ACCESS

Drugs / interventions tested

Conditions studied

Sponsor

The University of Texas Health Science Center at San Antonio

Who can join

18 and older, female only, with Uterine Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Single patient treatment with everolimus.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Everolimus

Trials testing the same drug.

Other recruiting trials for Uterine Sarcoma

Currently open trials in the same condition.

Other The University of Texas Health Science Center at San Antonio trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03493165.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing